News from Thursday, May 7, 2026
Articles
Ketamine Quickly Reduced Suicidal and Depressive Symptoms, Meta-Analysis Suggests
(5/6, Shannon Firth, Medpage Today) reports “...Across 26 randomized trials involving over 1,100 patients, those who received a single ketamine infusion had a significant reduction in suicidal symptoms compared with a control group at 24 hours...Martin Plöderl, PhD, of the Christian Doppler Clinic at Paracelsus Medical University in Salzburg, Austria, who was not involved with the study, called the effects ‘clinically meaningful and larger than conventional antidepressants.’” Full
Real World Data Reveal Persistent Gaps in Long Term IBD Control
(5/7, Bree Foster, PhD, Drug Discovery News) reports “...Despite advances in biologic and targeted therapies, real-world data presented at DDW 2026 suggest that many patients with IBD continue to experience recurrent periods of poor disease control. ‘This study examined real-world patterns of suboptimal treatment in patients with CD and UC, with the aim of better understanding the gap between what is clinically achievable and what patients are actually receiving in routine care,’ David Rubin, gastroenterologist at the University of Chicago and lead author of the study, told DDN.” Full
EU Joint Clinical Assessments: HTA Agencies Reveal Early PICO Learnings
(5/7, Francesca Bruce, Pink Sheet) reports “...In their joint clinical assessment dossiers, companies must justify any failure to answer key questions from EU member states on population, intervention, comparators and outcomes, health technology assessment agencies told the Pink Sheet.” Subscription Required
EU Joint Clinical Assessments: Prepare Early, Present Everything, Advise HTA Agencies
(5/7, Francesca Bruce, Pink Sheet) reports “...Several health technology assessment bodies carrying out EU-level joint clinical assessments shared their thoughts with the Pink Sheet on how drug companies can ensure their submissions are up to scratch.” Subscription Required
Press Releases
New Research Could Reshape How Future NHS Treatments Are Evaluated
(5/6, University of Sheffield Press Release) “...Professor Donna Rowen, Professor of Health Economics and project lead said, ‘The UK EQ-5D-5L value set has used state-of-the-art methods to ensure the values represent current preferences of the UK public around how different aspects of their health are valued. ‘Implementation of the value set by NICE would enable these findings to be used to shape decisions, representing an improvement on the use of values that are now outdated.’” Full
Journals
NetMetaEasy: Enabling Rapid and User-friendly Network Meta-Analysis (NMA) for Comparative Effectiveness Research
János Tibor Fekete, et al.
May 2026, British Journal of Pharmacology
Semaglutide vs. Bariatric Surgery: Comparing Costs and Clinical Outcomes in Patients With Diabetes and Obesity
Karan R. Chhabra, et al.
May 6, 2026, Obesity
Choice of Estimands and Estimators Affected the Interpretation of Results for Some Outcomes in a Cluster-Randomised Trial (RESTORE) Due to Informative Cluster Size
Dongquan Bi, et al.
May 6, 2026, medRxiv
Survival, Toxicity, and Economic Outcomes of Osimertinib Versus Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
Po-Huang Chen, et al.
May 6, 2026, JCO Oncology Practice
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis (NOSES): Protocol for a Comparative Effectiveness Randomized Controlled Trial
Daniel Merenstein, et al.
May 6, 2026, PLOS One
Baseline Epidemiological Differences Between Donanemab and Lecanemab Users in Real-World Settings: A Retrospective Cohort Study
Filipi Fim Andreão, et al.
May 7, 2026, Neurodegenerative Disease Management